Showing 1021-1030 of 21418 results for "".
- Combined Radiofrequency and Muscle Stimulation Improves Facial Wrinkles in Randomized Trialhttps://reachmd.com/news/combined-radiofrequency-and-muscle-stimulation-improves-facial-wrinkles-in-randomized-trial/2488692/An integrated treatment combining radiofrequency (RF), microneedle radiofrequency (MNRF), and dynamic muscle stimulation (DMSt) significantly improved facial wrinkles and overall aesthetic appearance in patients with moderate-to-severe facial wrinkles, according to findings from a prospective ran
- SYX-5219 Improves Eczema Severity, Itch in Early Clinical Trialhttps://reachmd.com/news/syx-5219-improves-eczema-severity-itch-in-early-clinical-trial/2488689/An investigational oral therapy targeting immune cell metabolism demonstrated improvements in disease severity and itch among adults with moderate to severe atopic dermatitis (AD), according to Phase 1b results announced by Sitryx Therapeutics. SYX-5219, a first-in-class pyruvate kinase M2
- Deuruxolitinib Hair Regrowth Responses Similar With or Without Nail Involvement in Severe Alopecia Areatahttps://reachmd.com/news/deuruxolitinib-hair-regrowth-responses-similar-with-or-without-nail-involvement-in-severe-alopecia-areata/2488685/Baseline nail involvement was not associated with a statistically significant difference in scalp hair regrowth among adults with severe alopecia areata receiving deuruxolitinib 8 mg twice daily, according to a pooled post hoc analysis of the phase 3 THRIVE-AA1 and THRIVE-AA2 trials presented at
- Tapinarof Improves Pediatric Sleep and Family Sleep Impact in ADORING Trial Analysishttps://reachmd.com/news/tapinarof-improves-pediatric-sleep-and-family-sleep-impact-in-adoring-trial-analysis/2488684/Once-daily tapinarof cream 1% was associated with greater improvements in sleep-related symptoms than vehicle among children with atopic dermatitis (AD), according to a post hoc analysis of the phase 3 ADORING 1 and ADORING 2 trials. Mark Boguniewicz, MD, and colleagues evaluated pooled da
- Envudeucitinib Improves Itch by Week 2 in Phase 3 Plaque Psoriasis Trialshttps://reachmd.com/news/envudeucitinib-improves-itch-by-week-2-in-phase-3-plaque-psoriasis-trials/2488683/Investigational oral tyrosine kinase 2 (TYK2) inhibitor envudeucitinib produced clinically meaningful itch improvement as early as week 2 in patients with moderate-to-severe plaque psoriasis, according to 24-week results from the phase 3 ONWARD1 and ONWARD2 trials. Jason E. Hawkes, MD, and
- Pediatric Nemolizumab Study Reports Improvements in Atopic Dermatitis Through 52 Weekshttps://reachmd.com/news/pediatric-nemolizumab-study-reports-improvements-in-atopic-dermatitis-through-52-weeks/2488676/Weight-based nemolizumab administered with topical therapy was associated with improvements in skin lesions and itch in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to phase 2 findings presented at the 2026 Fall Clinical Dermatology Conference. Lawr
- GLP-1 Medication Use Shows No Apparent Impact on Icotrokinra Outcomes in Phase 3 Psoriasis Analysishttps://reachmd.com/news/glp-1-medication-use-shows-no-apparent-impact-on-icotrokinra-outcomes-in-phase-3-psoriasis-analysis/2488675/Concomitant use of glucagon-like peptide-1 (GLP-1)–based medications was not associated with an apparent difference in icotrokinra efficacy, safety, or pharmacokinetics among patients with plaque psoriasis, according to pooled post hoc analyses of the phase 3 ICONIC clinical trial program present
- KRAS/TP53 Co-Mutation Linked to Better ICI Outcomes in LUADhttps://reachmd.com/news/krastp53-co-mutation-linked-to-better-ici-outcomes-in-luad/2488660/Key Takeaways Immunotherapy-treated patients with KRAS-mutant lung adenocarcinoma and concurrent TP53 mutation had significantly longer progression-free survival in two retrospective cohorts. Tested mutant p53 variants reduced SPP1 expression; experiments in selected
- Tonsillar IF-Tfh Cells Linked to IgA Nephropathy Activityhttps://reachmd.com/news/tonsillar-if-tfh-cells-linked-to-iga-nephropathy-activity/2488668/Key Takeaways Tonsils removed from patients with IgAN at two Japanese hospitals had a higher IF-Tfh fraction than tonsils from recurrent tonsillitis, palmoplantar pustulosis, or obstructive sleep apnea syndrome donors. Greater tonsillar IF-Tfh frequency in IgAN was a
- Checkpoint Inhibitor Rheumatic Toxicity in ERIN Registryhttps://reachmd.com/news/checkpoint-inhibitor-rheumatic-toxicity-in-erin-registry/2488665/Key Takeaways Among German rheumatology-referred adults receiving checkpoint inhibitors, rheumatoid arthritis–like polyarthritis was the leading rheumatic adverse-event phenotype. Rheumatic events were moderate or severe in 90%, and 38.3% of patients permanently disc